MedTrace Logo

Stereotactic Body Radiotherapy for Spine Tumors

NCT01347307 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-06-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.

Conditions

  • Spinal Metastases
  • Vertebral Metastases
  • Benign Spinal Tumors
  • Chordoma
  • Meningioma
  • Schwannoma
  • Neurofibroma
  • Paragangliomas
  • Arteriovenous Malformations

Interventions

RADIATION

SBRT for Benign Extradural Spine Tumors

14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)

RADIATION

SBRT for Vertebral/Paraspinal Metastases

12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)

Sponsors & Collaborators

  • Mercy Research

    lead OTHER

Principal Investigators

  • Bethany Sleckman, MD · Mercy Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01347307 on ClinicalTrials.gov